For children with SARS-CoV-2 infection, elevated body mass index (BMI) is associated with an increased risk of postacute sequelae of SARS-CoV-2 infection (PASC).
The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.
Among privately insured patients, there was a doubling in the use of GLP-1 RAs as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6% decrease in the rate of metabolic bariatric surgery ...